Results 51 to 60 of about 28,276 (143)

Microparticles of Lamivudine—Poly-ε-Caprolactone Conjugate for Drug Delivery via Internalization by Macrophages

Molecules, 2019
The past decade may be considered as revolutionary in the research field focused on the physiological function of macrophages. Unknown subtypes of these cells involved in pathological mechanisms were described recently, and they are considered as ...
Tomasz Urbaniak, Daniela Machová, Olga Janoušková, Witold Musiał   +3 more
doaj   +1 more source

The Epidemiology of HIV‐1 Resistance to Two‐Drug Regimens in Multicenter Cohort From Poland—A Cross‐Sectional Study

Health Science Reports, Volume 9, Issue 3, March 2026.
ABSTRACT Background and Aims Concerns about antiretroviral therapy failure are growing among people with HIV receiving two‐drug regimens, as these schemes include fewer active agents, while the prevalence of transmitted resistance in HIV‐1 continues to increase.
Andrzej Załęski, Agnieszka Lembas, Joanna Osińska, Tomasz Dyda, Magdalena Suchacz, Justyna Stempkowska‐Rejek, Justyna Orzechowska, Alicja Wiercińska‐Drapało   +7 more
wiley   +1 more source

Hepatitis B genotype G and high frequency of lamivudine-resistance mutations among human immunodeficiencyvirus/hepatitis B virus co-infected patients in Brazil

Memorias do Instituto Oswaldo Cruz, 2010
In this study, we evaluated the hepatitis B virus (HBV) genotype distribution and HBV genomic mutations among a group of human immunodeficiency virus-HBV co-infected patients from an AIDS outpatient clinic in São Paulo.
Adriana Cristina da Silva, Ângela Maria Miranda Spina, Marcílio Figueiredo Lemos, Isabel Takano Oba, Cristina de Fátima Guastini, Michele Soares Gomes-Gouvêa, João Renato Rebello Pinho, Maria Cássia Jacintho Mendes-Correa   +7 more
doaj   +1 more source

Efficacy of Dolutegravir Plus Lamivudine in People With TB/HIV Co‐Infection Using a Rifampicin or Rifabutin‐Based Regimen: A Retrospective Observational Case Series

Immunity, Inflammation and Disease, Volume 14, Issue 3, March 2026.
ABSTRACT Introduction Co‐infection with tuberculosis (TB) is the leading cause of death in individuals infected with human immunodeficiency virus (HIV)‐1. Dolutegravir and lamivudine (DTG + 3TC) has recently been recommended as the preferred first‐line regimen for the treatment of new and treatment‐experienced HIV‐infected patients.
Jinhong He, Xiangxi He, Xiaoxin Xie, Yanhua Fu, Xingxing Luo, Yinshuang Peng, Bin Xu, Hai Long   +7 more
wiley   +1 more source

Entecavir monotherapy versus de novo combination of lamivudine and adefovir for compensated hepatitis B virus-related cirrhosis: a real-world prospective multicenter cohort study

Infection and Drug Resistance, 2019
Xiaoning Wu,1–3,* Jialing Zhou,1–3,* Wen Xie,4 Huiguo Ding,5 Xiaojuan Ou,1–3 Guofeng Chen,6 Anlin Ma,7 Xiaoyuan Xu,8 Hui Ma,9 Youqing Xu,10 Xiaoqing Liu,11 Tongtong Meng,1–3 Lin Wang,1–3 Yameng Sun,1–3 Bingqiong Wang,1&
Wu X, Zhou J, Xie W, Ding H, Ou X, Chen G, Ma A, Xu X, Ma H, Xu Y, Liu X, Meng T, Wang L, Sun Y, Wang B, Kong Y, Ma H, You H, Jia J   +18 more
doaj  

Patterns of hepatitis B virus infection in Brazilian human immunodeficiency virus infected patients: high prevalence of occult infection and low frequency of lamivudine resistant mutations

Memorias do Instituto Oswaldo Cruz, 2006
Hepatitis B virus (HBV) molecular profiles were determined for 44 patients who were infected with human immunodeficiency virus (HIV) type 1 and had antibodies to the hepatitis B core antigen (anti-HBc), with and without other HBV serological markers.
Michel VF Sucupira, Francisco CA Mello, Eneida A Santos, Christian Niel, Valeria C Rolla, Juçara Arabe, Selma A Gomes   +6 more
doaj   +1 more source

Abnormal coagulation profile in people living with HIV-AIDS on combined Antiretroviral Therapy: findings from a case-control study in the Ho municipality, Ghana

The Pan African Medical Journal, 2018
INTRODUCTION: Although combined Anti-Retroviral Therapy (cART) has improved the quality of life and survival in people living with HIV-AIDS (PLWHA), there have been reports of increased non-AIDS related co-morbidities such as coagulopathies.
Richard Kobina Dadzie Ephraim, James Elikem Ahadzie, Patrick Adu, Joseph Boachie, Hope Agbodzakey, Prince Adoba, Obed Cudjoe   +6 more
doaj   +1 more source

Overcoming barriers, driving progress: Clinical science at IAS 2025

Journal of the International AIDS Society, Volume 29, Issue 3, March 2026.
Abstract Introduction The 13th IAS Conference on HIV Science, held in Kigali, Rwanda (13–17 July 2025), highlighted key advances in clinical research. Presentations focused on sustaining HIV treatment and prevention amid financial constraints, innovations in long‐acting oral antiretrovirals, and the management of comorbidities and co‐infections ...
Ezequiel Cordova, Simiso Sokhela, Jasmini Alagaratnam, Juan Ambrosioni   +3 more
wiley   +1 more source

Trends and Patterns of Adverse Drug Reaction Reporting in Sierra Leone: A Retrospective Analysis of VigiFlow Data (2008–2022)

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 3, March 2026.
ABSTRACT Purpose Adverse drug reactions (ADRs) present significant obstacles for healthcare systems, impacting both patient safety and the effectiveness of treatments. Despite this, there is a scarcity of research on ADR reports in Sierra Leone, especially over long periods.
Isatu Jalloh, Onome Thomas Abiri, Peter Bai James, Rajesh Vagiri, Neelaveni Padayachee   +4 more
wiley   +1 more source

Unusual case of lamivudine-associated skin rashes in an HIV/AIDS patient: a case presentation

Archives of Pharmacy Practice, 2017
In patients with human immunodeficiency virus (HIV) infection, lamivudine is used as a first-line drug for antiretroviral therapy. Lamivudine is relatively nontoxic in nature, and it can also be used during pregnancy.
Kashif U Khan, Amer H Khan, Syed A Sulaiman, Chow T Soo, Syed I Ahmad   +4 more
doaj   +1 more source